Neuro-ophthalmologic manifestations of sarcoidosis

Barney Stern, James Corbett

Research output: Contribution to journalReview article

Abstract

The first-line treatment for the neuro-ophthalmologic manifestations of sarcoidosis is corticosteroid therapy. Prednisone, 0.5 to 1 mg/kg/day, is initially prescribed for 2 to 4 weeks, before a slow taper is begun as the patient's symptoms and examination are monitored. Patients frequently require adjunct therapy, which can be in the form of immunomodulatory drugs such as pentoxyfillin, hydroxychloroquine, or thalidomide, or immunosuppressive drugs such as mycophenolate mofetil, azathioprine, methotrexate, and cyclophosphamide. Individuals with profound visual compromise or progressive disease may benefit from high-dose intravenous methylprednisolone or tumor necrosis factor-α antagonists such as infliximab. Attention to the overall medical status of the patient is essential to ensure that an optimal clinical status is achieved.

Original languageEnglish (US)
Pages (from-to)63-71
Number of pages9
JournalCurrent Treatment Options in Neurology
Volume9
Issue number1
DOIs
StatePublished - Jan 1 2007
Externally publishedYes

Fingerprint

Sarcoidosis
Mycophenolic Acid
Hydroxychloroquine
Thalidomide
Methylprednisolone
Azathioprine
Immunosuppressive Agents
Prednisone
Methotrexate
Pharmaceutical Preparations
Cyclophosphamide
Adrenal Cortex Hormones
Therapeutics
Tumor Necrosis Factor-alpha

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Neuro-ophthalmologic manifestations of sarcoidosis. / Stern, Barney; Corbett, James.

In: Current Treatment Options in Neurology, Vol. 9, No. 1, 01.01.2007, p. 63-71.

Research output: Contribution to journalReview article

@article{5a601138e99244efa21bb160e4797ec9,
title = "Neuro-ophthalmologic manifestations of sarcoidosis",
abstract = "The first-line treatment for the neuro-ophthalmologic manifestations of sarcoidosis is corticosteroid therapy. Prednisone, 0.5 to 1 mg/kg/day, is initially prescribed for 2 to 4 weeks, before a slow taper is begun as the patient's symptoms and examination are monitored. Patients frequently require adjunct therapy, which can be in the form of immunomodulatory drugs such as pentoxyfillin, hydroxychloroquine, or thalidomide, or immunosuppressive drugs such as mycophenolate mofetil, azathioprine, methotrexate, and cyclophosphamide. Individuals with profound visual compromise or progressive disease may benefit from high-dose intravenous methylprednisolone or tumor necrosis factor-α antagonists such as infliximab. Attention to the overall medical status of the patient is essential to ensure that an optimal clinical status is achieved.",
author = "Barney Stern and James Corbett",
year = "2007",
month = "1",
day = "1",
doi = "10.1007/s11940-007-0032-3",
language = "English (US)",
volume = "9",
pages = "63--71",
journal = "Current Treatment Options in Neurology",
issn = "1092-8480",
publisher = "Current Science, Inc.",
number = "1",

}

TY - JOUR

T1 - Neuro-ophthalmologic manifestations of sarcoidosis

AU - Stern, Barney

AU - Corbett, James

PY - 2007/1/1

Y1 - 2007/1/1

N2 - The first-line treatment for the neuro-ophthalmologic manifestations of sarcoidosis is corticosteroid therapy. Prednisone, 0.5 to 1 mg/kg/day, is initially prescribed for 2 to 4 weeks, before a slow taper is begun as the patient's symptoms and examination are monitored. Patients frequently require adjunct therapy, which can be in the form of immunomodulatory drugs such as pentoxyfillin, hydroxychloroquine, or thalidomide, or immunosuppressive drugs such as mycophenolate mofetil, azathioprine, methotrexate, and cyclophosphamide. Individuals with profound visual compromise or progressive disease may benefit from high-dose intravenous methylprednisolone or tumor necrosis factor-α antagonists such as infliximab. Attention to the overall medical status of the patient is essential to ensure that an optimal clinical status is achieved.

AB - The first-line treatment for the neuro-ophthalmologic manifestations of sarcoidosis is corticosteroid therapy. Prednisone, 0.5 to 1 mg/kg/day, is initially prescribed for 2 to 4 weeks, before a slow taper is begun as the patient's symptoms and examination are monitored. Patients frequently require adjunct therapy, which can be in the form of immunomodulatory drugs such as pentoxyfillin, hydroxychloroquine, or thalidomide, or immunosuppressive drugs such as mycophenolate mofetil, azathioprine, methotrexate, and cyclophosphamide. Individuals with profound visual compromise or progressive disease may benefit from high-dose intravenous methylprednisolone or tumor necrosis factor-α antagonists such as infliximab. Attention to the overall medical status of the patient is essential to ensure that an optimal clinical status is achieved.

UR - http://www.scopus.com/inward/record.url?scp=33847345463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847345463&partnerID=8YFLogxK

U2 - 10.1007/s11940-007-0032-3

DO - 10.1007/s11940-007-0032-3

M3 - Review article

C2 - 17288891

AN - SCOPUS:33847345463

VL - 9

SP - 63

EP - 71

JO - Current Treatment Options in Neurology

JF - Current Treatment Options in Neurology

SN - 1092-8480

IS - 1

ER -